AstraZeneca : A transformative deal that further boosts AstraZeneca’s growth
>Friendly takeover bid on rare disease specialist Alexion - AstraZeneca announced at the weekend a friendly takeover bid for Alexion, a specialist in rare diseases in immunology, a company with sales of close to $ 5bn in 2019 and an EBITDA margin of 50%. The $39.4 billion transaction will be paid one-third in cash ($ 60 per share) and two-thirds in shares (2.1243 AZN ADS per share). Finally, the price paid by AstraZeneca at $ 175 per share represents a 45% premium to...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.